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Modern radiation therapy is delivered with great precision, in part by relying on high-resolution multidimensional
anatomic imaging to define targets in space and time. The development of quantitative imaging (QI) modalities capable
of monitoring biologic parameters could provide deeper insight into tumor biology and facilitate more personalized clin-
ical decision-making. The Quantitative Imaging Network (QIN) was established by the National Cancer Institute to
advance and validate these QI modalities in the context of oncology clinical trials. In particular, the QIN has significant
interest in the application of QI to widen the therapeutic window of radiation therapy. QI modalities have great promise
in radiation oncology and will help address significant clinical needs, including finer prognostication, more specific
target delineation, reduction of normal tissue toxicity, identification of radioresistant disease, and clearer interpretation
of treatment response. Patient-specific QI is being incorporated into radiation treatment design in ways such as dose
escalation and adaptive replanning, with the intent of improving outcomes while lessening treatment morbidities. This
review discusses the current vision of the QIN, current areas of investigation, and how the QIN hopes to enhance the
integration of QI into the practice of radiation oncology.  2018 Elsevier Inc. All rights reserved.Introduction
Quantitative imaging (QI) is defined as the extraction of
quantifiable radiologic biomarkers from medical images
for the assessment of the severity, degree of change, or
status of a disease or chronic condition relative to normal
(1). Its application in oncology is rapidly expanding for
diagnosis, staging, and treatment response assessment (2).
The use of quantitative metrics in radiation oncology for
treatment planning and response assessment has distinct
advantages over subjective imaging metrics by providing
deeper insight into tumor macro- and microenvironments,
correlating with genomic markers (3), and demonstrating
associations with radiation therapy (RT) susceptibility and
changes in the microenvironment after RT (4, 5).
The National Cancer Institute (NCI) has recognized
the importance of QI by funding the Quantitative Imaging
Network (QIN) since 2008 under the Cancer Imaging
Program (6). The QIN supports use of QI for clinical
decision-making in oncology through the development
and validation of tools for standardizing image acquisi-
tion, processing, and analysis. These tools use analytical
algorithms for data quantification to enable personalized
treatment for individual patients and the prediction and
monitoring of response to drugs or RT (7).Radiation oncology is increasingly reliant on both
qualitative anatomic-based imaging, such as computed
tomography (CT) and T1- and T2-weighted magnetic
resonance imaging (MRI), and on QI, such as positron
emission tomography (PET), single-photon emission CT,
diffusion weighted imaging (DWI), and magnetic reso-
nance spectroscopy (MRS). Although the QIN focuses on
a wide range of clinical oncologic applications, there is
growing interest in producing QI tools specifically to
enhance clinical efficacy within radiation oncology. For
example, QI has potential to improve prognostication of
response to RT which could facilitate personalized treat-
ment decisions and assist in clinical trial design. Func-
tional QI can better identify disease extension beyond
conventional imaging techniques, which has become
increasingly important as advancements in RT treatment
planning and delivery enable increasingly conformal dose
distributions. These imaging advances also can provide
technical support for treatment strategies such as hetero-
geneous “dose painting” based on personalized risk (eg,
intratumoral hypoxia) and adaptive treatments based on
anatomic or functional responses. Ultimately, QI tech-
niques may feed image-derived quantities directly into
patient-specific computations of dose. Therefore, under-
standing and quantifying image-derived signals are a
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at large.
Tools needed to optimize the use of QI in the RT
workflow are currently underdeveloped and incomplete.
Many labor intensive and often subjective steps in treat-
ment planning, such as manual contouring of target struc-
tures, could be optimized by integrating validated QI
parameters, including correction algorithms to diminish the
effects of known variables (8) and the development of a
quantitative data-substantiated workflow that minimizes
errors based on known limitations in the current process
(9). Algorithm-driven tools to expedite image analysis
through automation specifically to assist the radiation on-
cologist’s clinical decision-making are under development
by members of the QIN with the goal to maximize the
potential of QI. Additionally, implementation of QI into
clinical radiation oncology practice requires sophisticated
data management, informatics, and statistical analysis,
however due to space considerations these topics will not
be addressed in this review.
The QIN endorses the exciting potential of QI to ulti-
mately widen the therapeutic window of RT. In this review,
the state of QI in the context of RT design, delivery, and
response assessment will be discussed, with an emphasis on
ongoing and proposed QIN initiatives related to radiation
oncology (10).CT Imaging
Historically, CT imaging has been the backbone of RT
planning, providing 3-dimensional (3D) anatomic infor-
mation and a reliable spatial platform to quantitatively es-
timate electron density required for dose calculations.
Advances in CT imaging include thin-sliced high-resolu-
tion acquisitions; 4-dimensional CT that visualizes respi-
ratory motion and thereby allows for respiratory gating of
treatment; and dual-energy CT, in which 2 CT datasets are
acquired using different photon spectra (11) to improve
both tissue differentiation and quantification of dose cal-
culations for photon (12, 13) and particle therapy (14).
Other work is ongoing to use other quantitative CT mo-
dalities, such as dynamic contrast-enhanced CT, to improve
target delineation in specific instances (eg, vascular le-
sions), to assess perfusion (15, 16), to assess response to RT
and antiangiogenic therapies (17-21), and potentially to
predict outcomes after RT (22-24).
In the QIN, there is particular interest in using CT-based
quantitation of radiomic features in applications within
radiation oncology. This area of bioinformatics uses images
as mineable data to develop models that can enhance
diagnostic accuracy, prognostic capability, and response
prediction (25, 26). Specific to RT, analysis of pretreatment
CT-based radiomic features has been used to predict for
overall survival and patterns of failure after chemoradiation
in both non-small cell lung cancer (NSCLC) and head and
neck cancer (HNC) (27-29) and in early staged NSCLCtreated with stereotactic body RT (30-32). More recently,
this type of feature analysis has been used to predict for
pathologic responses in NSCLC after neoadjuvant chemo-
radiation (33, 34), and further work is being performed to
discern the predictive value of feature differences from pre-
to post-RT CT scans (35).
Radiomics applications rely on large data sets and
unique analysis tools to evaluate a wide variety of imaging
features for clinical relevance. For example, a QIN group
from the Dana-Farber Institute tested 440 CT-based fea-
tures that quantified tumor intensity (ie, Hounsfield units),
shape, and/or texture in a CT dataset containing 1019 pa-
tients treated with chemoradiation for either NSCLC or
HNC. Using a smaller training data set, the authors corre-
lated certain imaging features (eg, intratumor heterogene-
ity) with gene-expression profiles and clinical outcomes.
The selected feature set was confirmed in the validation
dataset to be predictive of overall survival and certain
molecular expression profiles (29). Other QIN in-
vestigations have assessed and confirmed the reproduc-
ibility of these features using test-retest analyses (36) and
the robustness of image features across various extraction
algorithms in a multidisciplinary setting (37).
To improve the efficiency of QI integration into
standard workflow, QIN researchers at Stanford Univer-
sity developed a QI informatics platform called the
electronic Physicians Annotation Device (ePAD). This
program provides the ability to quickly perform lesion
measurements and repurpose image data to more easily
evaluate QI imaging biomarkers across radiologic studies
such as CT scans. The device has been shown to reduce
the time needed to evaluate scans (38) and could provide
a more efficient platform to validate other QI/radiomic
parameters as well as an opportunity for rapid analysis
needed for online adaptation of therapy. Segmentation
algorithms also could assist radiation oncology workflow
by providing reliable and accurate contouring target
delineation (eg, of lung nodules) (39). The QIN recently
completed the Lung CT segmentation QIN challenge,
which compared the accuracy and precision of several
segmentation algorithms (40). Another example includes
a recently validated semiautomated fluorodeoxyglucose
(FDG)-PETebased segmentation algorithm for HNC (9).
Further development of these tools could fundamentally
affect the workflow of RT treatment planning. Although
clinical use of quantitative CT parameters is limited to
date, its future potential is easy to envision and remains
an active area of research in the QIN. Eventually, these
tools may also aid in dose selection based on feature
analysis, including evaluation of perfusion and identifi-
cation of necrosis.PET Imaging
PET is an inherently quantitative modality because its
output is based on the temporal and spatial summation of
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uptake value (SUV). A wide range of PET radiotracers
are available or in development that offer high sensitivity
and specificity of numerous in vivo biologic and mo-
lecular processes. Currently, only [18F]-FDG, Na[18F],
18fluciclovine, [11C]-choline, and [68Ga]-DOTA-octreo-
tate (DOTATATE) are approved by the U.S. Food and
Drug Administration for oncologic indications, but many
others are being evaluated in clinical trials. Identification
of quantifiable imaging biomarkers for a variety of bio-
logical processes (eg, metabolism, hypoxia, and prolif-
eration) are of interest to the QIN because of their
tremendous potential in personalizing cancer care.FDG-PET
[18F]-FDG is the most commonly used PET radiotracer in
the clinic. It relies on the correlation of glucose meta-
bolism with the upregulation of glucose transporters in
cancer cells and has important roles in patient staging,
selection, and RT target delineation in numerous disease
sites, including NSCLC (41), small cell lung cancer (42),
HNC (43, 44), pancreatic cancer (45), lymphoma (46,
47), anal cancer (48), and rectal cancers (49). However,
using [18F]-FDG PET for fine target delineation is
generally limited by its relatively low image resolution of
5 to 10 mm. Target delineation can be affected further
based on which segmentation method is used (eg, indi-
vidual visualization, SUV-threshold, or segmentation
algorithms) (50-53). A multi-institutional evaluation of
PET segmentation performed by the QIN reported a wide
range of volume errors, emphasizing the need for stan-
dardized methods in future trials (51). Differences in
image acquisition, treatment position, respiratory motion
(54), image registration (55), and technical factors with
individual scanners also affect eventual SUV-based
contours (56). The QIN recently completed the QIN
PET Segmentation Challenge, a comparison of PET
phantom data sets used to assess the variability of seg-
mentation models, and subsequently derived quantitative
analysis results. Final results of this challenge may
provide insights into how to improve multi-institutional
quantitative PET image analysis performance and
emphasize the importance of robust quality assurance
during the development of automated PET-based target
delineation protocols.
Another important role for PET imaging in radiation
oncology is its use in early response assessment. The use
of [18F]-FDG to assess early responses to chemotherapy is
well established in the literature (57-62), and similar
studies have assessed response to chemoradiation. For
example, in NSCLC, [18F]-FDG PET scans obtained by
the fifth week of definitive chemoradiation have demon-
strated ability to differentiate responders from non-
responders (63, 64) and to predict for overall survival (65).
Midtreatment [18F]-FDG PET scans have demonstratedsimilar prognostic ability after chemoradiation in other
cancers, including cervical cancer (66, 67), rectal cancer
(68), and HNC (69). Figure 1 shows an example of tumor
FDG-uptake quantification at different time points during
treatment.
At this time, the utility of [18F]-FDG PET response
assessment after RT alone is less clear. Trials have re-
ported predictive SUV changes after chemoradiation but
not after RT alone (68), suggesting that, in some cases, the
predictive metabolic changes may be driven primarily by
the chemotherapy component. In addition, the interpreta-
tion of SUV changes after RT can be confounded by
radiation-induced normal tissue inflammation affecting
[18F]-FDG uptake. In vitro studies show early flares in
FDG uptake in tumor cells, followed by response, but such
changes are less frequent in vivo (70). Given the accu-
mulation of inflammation throughout a radiation course,
the optimal timing for assessment will be important to
establish in future studies. Despite these limitations, there
remains great enthusiasm for early PET assessments in
radiation oncology, and QIN investigators continue to
examine an increasing role for [18F]-FDG PET in this
capacity.
An exciting application of this strategy is the use of a
midtreatment [18F]-FDG PET scan as a functional
biomarker to facilitate adaptive dose escalation to poorly
responding disease. Kong et al recently conducted a phase
II PET-adapted RT trial for patients with NSCLC (N Z 42)
undergoing chemoradiation using interim [18F]-FDG PET
at 45 Gy to identify regions of poorly responding disease,
which were then targeted up to 86 Gy (71). The 2-year
infield disease control rate of 82% was a considerable
improvement from Radiation Therapy Oncology Group
(RTOG) 0617, which had a 2-year infield control rate of
61% to 69%. Given these promising results with PET-
adapted dose escalation, this strategy is now the basis for
RTOG 1106, a phase II randomized trial that has accrued
fully and is awaiting initial analysis. An example is shown
in Figure 2 demonstrating the predictive value of mid-
treatment [18F]-FDG PET. There are several ongoing clin-
ical trials that include early response assessment in rectal
cancer (NCT02233595, University of California, San
Francisco) and glioblastoma (NCT02902757, University of
California, Los Angeles) and early response assessment
with adaptive replanning in NSCLC (NCT02773238, Uni-
versity of Washington; NCT02492867, University of
Michigan).
An important hurdle that must be addressed before the
implementation of FDG-based parameters to dictate treat-
ment decisions and define target volumes in multicenter
clinical trials is the need to standardize scanner output,
segmentation methods, and analysis tools (72). For
example, inherent variability in adjusted [18F]-FDG PET
SUV from individual scanners can range over 20% (73), but
QIN investigators at the University of Washington reduced
error to less than 4% using routine calibration protocols
(74). Deviations in the time between radiotracer injection
Fig. 1. FDG-PET demonstrates the ability to quantify gross tumor metabolic volume at baseline and after radiation therapy
for the purposes of assessing response and to provide a predictive biomarker of early therapeutic efficacy. Rows 1 and 2:
Baseline PET/CTdThe magenta is the lesion volume of interest, which was automatically generated based on PET intensity
gradients. Rows 3 and 4: Follow-up PET/CTdMagenta is original volume of interest deformed to match the patient’s
anatomy on follow-up CT image. Blue is the lesion volume of interest automatically generated based on PET intensity
gradients in the follow-up PET image. Row 5: Color-coded normalized SUV voxel-by-voxel subtraction fused with CT. This
allows a full 3-dimensional comparison of regions of response and nonresponse in a large heterogeneous tumor. (A color
version of this figure is available at https://dx.doi.org/10.1016/j.ijrobp.2018.06.023.)
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affect SUV values, suggesting the need for stricter imaging
protocols (75). Guidelines have been published to help
standardize image acquisition procedures (76). QIN groups
at the University of Washington and the University of Iowa
are actively working on both processing tools to improve
consistency and standardize protocols to limit outputvariations across institutions (77). To address the need for
broader standardization, the University of Washington
group developed the software program F-18 X-Cal System,
which allows for cross-calibration of PET scanners, dose
calibrators, and well detectors for Ga-68 and [18F] isotopes
in a multicenter setting. These steps to limit sources of error
may improve the sensitivity of trials investigating QI-based
Fig. 2. FDG-PET/CT images of 57-year-old man with base-of-tongue squamous cell carcinoma and a right level 2 cervical
metastasis undergoing therapy. The PET intensity gradient tool shown in Figure 1 was used to generate total glycolytic
volumes at baseline, early during therapy, and posttreatment. [18F]-FDG uptake between baseline and an early response
assessment time (day 21) was significantly reduced, with tumor glycolytic index decreasing from 87.6 standard uptake
volume-mL (SUV-mL) to 19.3 SUV-mL. At 5-month follow-up, the patient showed an excellent response with near complete
interval resolution of disease. Primary tumor uptake was reduced to background levels, with a measured tumor glycolytic
index of 7.0 SUV-mL. Nodal metastasis also had good therapy response. This figure illustrates that an early reduction in total
glycolytic volume can be used as a predictive biomarker. In this case, the large reduction in total glycolytic volumes at
3 weeks was predictive for a beneficial longer-term outcome.
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further refinement of accreditation standards for imaging
centers to participate in QI clinical trials will be needed
(78, 79).Postacquisition analysis and response interpretation is
another step that warrants further evaluation. Image pro-
cessing algorithms across vendors and institutions are
currently heterogeneous and will require standardization to
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been published to standardize the interpretation of post-
treatment PET responses, including the European Organi-
zation for Research and Treatment of Cancer (EORTC) (80)
and later the PET Response Criteria in Solid Tumors
(PERCIST) criteria with input by the NCI (81). However, a
limitation to incorporating PERCIST criteria into detailed
response assessments has been the lack of integrated
workflow tools. To improve automation of PERCIST
criteria, QIN investigators at Johns Hopkins University and
Washington University in St Louis have been involved in
the development and evaluation of the computer software
Auto-PERCIST (82). Automatic processes will allow for
computer-aided analysis, database integration, and auto-
mated report generation (9). In radiation oncology, a future
potential application of these automatic platforms could be
the rapid integration of FDG-SUV values into RT planning
software, which may assist in factors ranging from the
objective characterization of nonresponding tissues to
decision-making regarding RT boost volumes. Of note, the
SUV normalized for lean body mass (SUL) peak parameter
is emphasized in the Auto-PERCIST formulation because of
strong correlations between absolute SUVand body weight,
which proper correction to lean body mass minimizes (83).
In addition, SUL peak values are less subject to noise-
induced upward bias than are SUV max values (84).
Thus, when SUV-based cut-offs are used, close attention
must be paid to the specific quantitative metric applied and
the reconstruction parameters (85). SUL peak formulations
are increasingly recognized as more stable.Hypoxia PET
Tumor hypoxia is a known cause of radioresistance and can
vary widely among different individual tumors and tumor
types (86). Traditional measurements of tumor hypoxia
require direct in vivo probes or biopsy (87), but the
development of PET radiotracers (eg, [18F]-fluo-
romisonidazole (88), [18F]-fluoroazomycin arabinoside (89,
90), [18F]-flortanidazole (91), and Cu-ATSM (92)) now
allows for noninvasive visualization of various hypoxic
processes. Tumor hypoxia is often heterogeneous (93, 94),
implying that certain tumor subvolumes are more hypoxic
and, therefore, more radioresistant. Numerous prospective
studies involving HNC (95-97), glioblastoma (98, 99),
NSCLC (100, 101), cervix (102), and prostate (103) report
worse local control and overall outcomes for hypoxic tu-
mors after RT. Tumor hypoxia also has been shown to be
dynamic during RT (104), especially early in treatment,
indicating that reoxygenation could be used as an early
biomarker (97).
In radiation oncology, 2 open trials from Memorial
Sloan Kettering are examining the prognostic capability of
[18F]-MISO PET in rectal cancer (NCT00574353) and
NSCLC (NCT02016872) after RT. In addition, there is
great interest in using hypoxia PET to apply RT dosepainting to intensify the dose to hypoxic areas (105, 106). A
phase II trial in HNC has reported improved locoregional
control (107), and this strategy is being further investigated
in the German phase III ESCALOX trial (NCT01212354)
(108). Adaptive strategies are also under investigation,
including a recently accrued phase II trial at Stanford
University (NCT01507428) that is assessing the utility of
midtreatment [18F]-MISO PET in NSCLC.
Similar to [18F]-FDG PET, hypoxia imaging protocols
will need to be standardized to guide clinical trial design
with hypoxia PET radiotracers. A Canadian QIN group
from Princess Margret Cancer Centre/University Health
Network in Toronto is working to standardize acquisition
methodology, integrate other imaging methods to produce a
more robust tracer kinetic model, and develop software to
make analysis of quantitative hypoxia metrics more facile
(109). These efforts will be shared through the QIN to
facilitate multi-institutional retrospective studies containing
hundreds of hypoxia imaging datasets. In addition, a major
challenge to the clinical utility of hypoxia PET imaging
compared with other tracers, such as FDG, is the small
signal-to-background ratio of all known agents. It is
therefore crucial to develop hypoxia PET imaging bio-
markers that exhibit heightened sensitivity to hypoxia
relative to background tissue and that can be measured
reproducibly across different sites. Important questions that
are being addressed to achieve this goal include the choice
of optimal reference tissue (eg, blood or muscle) (110,
111), the choice of threshold for hypoxic status determi-
nation, and the need for dynamic PET modeling to correct
for tumor transport properties (ie, background) (112-114).
Ongoing trials seek to validate PET-hypoxia imaging bio-
markers against postresection pathology in pancreatic
cancer (NCT01542177) and assess their prognostic capa-
bilities in cervical cancer (NCT01549730).Proliferation PET
Imaging cellular proliferation is of intuitive interest to on-
cologists. [18F]-fluorothymidine (FLT) is a PET tracer that
relies on the upregulation of the enzyme thymidine kinase 1
during the S-phase of the cell cycle. Thymidine kinase 1
phosphorylates FLT, which fixes it intracellularly and leads
to accumulation in rapidly proliferating cells (115). [18F]-
FLT has several potential advantages over [18F]-FDG,
particularly for use after RT. First, [18F]-FLT PET has been
shown to quantify similar SUVs across multiple institutions
with excellent repeatability (116). Second, [18F]-FLT PET
measures may be more specific in assessing response to RT
because they are associated with a cellular process directly
related to cell proliferation rather than glycolysis, the latter
of which may be upregulated in both active tumor and
normal areas with radiation-induced inflammation. This
theory is supported by comparative studies of [18F]-FLT
and [18F]-FDG. For example, [18F]-FLT PET has demon-
strated greater success in identifying pathologic complete
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(117). Additionally, in contrast to [18F]-FDG, decreases in
[18F]-FLT SUV have shown predictive value after RT alone
(118). Together, these advantages suggest a wider potential
utility of [18F]-FLT PET in radiation oncology. These ad-
vantages, however, must be balanced against the lower
absolute SUV of [18F]-FLT in many cancers. Comparative
studies after chemotherapy alone have reported worse
predictive value of [18F]-FLT compared with [18F]-FDG
(119), indicating the need for caution until further
treatment-specific studies are available.
A major area of interest for use of [18F]-FLT PET is in
early response assessment during RT. Studies have evaluated
this strategy in HNC and NSCLC and generally demon-
strated improved tumor control with decreasing [18F]-FLT
uptake (120-122). However, a recent study by Everitt et al
conversely reported that stable uptake of [18F]-FLT at week
2 of chemoradiation for NSCLC was associated with
improved overall survival compared with complete or partial
FLT response. The authors hypothesized that reduced [18F]-
FLT uptake may have been associated with suppression of
tumor cell proliferation, resulting in decreased RT-induced
tumor cell mitotic death and, consequently, worse overall
outcomes. This finding has important implications because
it indicates potentially disparate kinetic responses between
radiotracers and emphasizes the need to validate biomarkers
before clinical implementation (122).
Another potential role for [18F]-FLT PET is to differ-
entiate tumor progression from treatment effect after RT.
This ability is being investigated in prospective trials for
both brain metastases (NCT02328300) and NSCLC
(NCT02456246). QIN researchers at the University of Iowa
have also investigated use of [18F]-FLT PET to identify and
avoid active (ie, proliferating) bone marrow in patients
when optimizing RT treatment plans. Implementing this
strategy has been shown to reduce the risk of leukopenia in
patients with pelvic malignancies, supporting this novel use
as a strategy to reduce treatment toxicity (123).Non-FDG metabolism PET
Numerous other radiotracers in addition to FDG have been
studied to exploit the inherent increased metabolic demands
within tumors. Choline (Cho) is an essential nutrient
required for Cho phospholipid metabolism (124). Amino
acid tracers, which rely on increased anabolic demands and
increased amino acid transport via LAT1 and LAT2, are
also under investigation. They appear particularly useful for
intracranial disease and include [11C]-methionine and 18-
fluoroethyl-tyrosine.
Several promising PET tracers specific to prostate can-
cer have been developed (125). Prostate-specific membrane
antigen (PSMA) is a semiquantitative tracer that can be
used in systemic staging and in guidance for salvage RT in
the setting of recurrences (126). In addition, anti-1-amino-
3-18F-fluorocyclobutane-1-carboxylic acid (FACBC) is asynthetic l-leucine analog that has demonstrated high up-
take in prostate cancer cells (127) and may play an
important role for RT treatment planning. A NCIespon-
sored randomized trial is ongoing to assess the clinical
significance of using FACBCePET during RT treatment
planning (NCT01666808). A current limitation of these
modalities is the semiquantitative method for volume seg-
mentation. The development of formal segmentation
methods would be clinically useful.
PET radiomics
In combination with CT-based radiomic analysis, PET
data can be mined to discern clinically relevant infor-
mation (128). For example, PET imaging biomarkers
have been reported to correlate with underlying
genomic phenotypes (129) and somatic mutation pat-
terns (130) to better predict clinical outcomes and direct
treatment decisions. Other clinical studies have sug-
gested PET-based radiomic analyses add predictive
value to [18F]-FDG PET in HNC (131), rectal cancer
(132), and cervical cancer (133). Textural analysis (eg,
coarseness) of 18-fluoroethyl-tyrosine PET scans along
with conventional imaging have also demonstrated
improved diagnostic accuracy in discerning radiation
necrosis from tumor progression in brain metastases,
suggesting its ability to enhance diagnostic discrimi-
nation after RT (134). QIN investigators from the Dana
Farber Cancer Institute at Harvard University are
developing radiomic analysis systems to correlate PET/
CT imaging features and genomic profiling to non-
invasively assess molecular features and monitor treat-
ment responses.
A major issue for PET-based radiomic analyses in-
volves the varying output of textural features on which the
SUV segmentation method is based. There appears to be
poor reliability between different analysis methods (135)
and a lack of reproducibility between features (131). The
standardization of these methodologies will be critical to
properly interpreting textural results, and the minimization
of such analytical variance remains a priority of the QIN.
MRI
MRI is a widely used imaging modality with distinct ability
to provide increased soft tissue contrast with high spatial
and temporal resolution. The importance of MRI in radia-
tion oncology continues to grow as treatment planning
becomes more dependent on reliable delineation of targets
and organs at risk. This reliance will likely continue to
grow stronger as linear accelerator systems become inte-
grated with MRI to provide live high-resolution image
guidance and facilitate adaptive replanning. Anatomic MRI
scans are primarily T1- and T2-weighted sequences that
can delineate normal from abnormal tissue. These MRI
scans can be obtained with fat or nonfat saturation pulse
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MRI sequencesdincluding perfusion, DWI with apparent
diffusion coefficient (ADC) mapping, diffusion tensor im-
aging (DTI), and spectroscopydcan provide additional
quantitative molecular and biological information in par-
allel with the highly detailed anatomy of routine T1/T2
sequences. QIN members are involved with several studies
assessing the clinical utility of these techniques and broadly
pursuing tools to advance the incorporation of quantitative
MRI in radiation oncology. Quantitative MRI could assist
greatly in patient selection, tumor delineation, prediction of
RT response, planning adaptation, and improved assess-
ment of overall treatment response.Perfusion MRI
Perfusion-weighted MRI sequences can interrogate the
vascularity of tissue and other parameters related to
perfusion. This modality leverages the frequently increased
vascularity of tumors resulting from abnormal angiogenesis
to provide insights into tumor biology. The 2 most common
methods of perfusion MRI are dynamic contrast enhanced
(DCE) MRI and dynamic susceptibility contrast (DSC)
MRI. These methods quantify changes in tissue contrast
over time by acquiring rapid MRI sequences before, during,
and after intravenous injection of a gadolinium-based
contrast agent. For DCE-MRI, dynamic T1-weighted im-
ages are obtained, and changes in contrast signal are
quantified. A variety of microvascular environment pa-
rameters can be calculated by fitting time-contrast intensity
curves (or time-contrast agent concentration curves) to
different pharmacokinetic (PK) models. Standard quanti-
tative PK parameters for DCE-MRI include (1) Ktrans, the
volume transfer constant between blood plasma and the
extracellular, extravascular space; (2) Kep, the redistribution
rate constant from the extracellular, extravascular space to
the blood plasma; and (3) Vp and Ve, the plasma and
extracellular, extravascular volume fractions, respectively
(136). For DSC-MRI, dynamic T2- or T2*-weighted se-
quences are obtained before and after a contrast bolus. The
changes in T2 or T2* relaxation times are measured and
applied to PK models to estimate different hemodynamic
parameters, including cerebral blood volume (CBV), cere-
bral blood flow, and mean transit time.
Clinical appreciation of the characterization of vascular
parameters is rapidly expanding. For intracranial malig-
nancies, perfusion parameters obtained from DSC (137,
138) and DCE (139-141) MRI scans have demonstrated
excellent ability to differentiate radiation necrosis from
tumor progression. Comparative studies of the 2 methods
have been reported (142), and further investigation is
needed to identify optimized parameters and modality
combinations. A study investigating DCE CT and DCE
MRI for brain metastases after stereotactic radiosurgery
reported high correlations if the same analysis platform is
used (16). Studies have also demonstrated the value ofearly changes in perfusion MRI to predict for survival
outcomes. American College of Radiation Imaging
Network (ACRIN) 6677/RTOG 0625 reported that early
decreases in the relative CBV were associated with
improved 1-year survival in patients with recurrent glio-
blastoma (143). Based on this finding, ECOG-ACRIN
initiated a phase II trial (NCT03115333) in which patients
with recurrent glioblastoma are treated with bevacizumab
and imaged with early DSC-MRI scans (2 weeks post-
therapy) to determine whether early relative CBV response
correlates with overall survival. These projects highlight
the QIN collaboration with ECOG-ACRIN (144), which
will expand the translational reach of the QIN and carry its
expertise into working group platforms of national coop-
erative groups. This partnership seeks to improve the value,
effectiveness, and efficiency of clinical trials while also
validating QI-based imaging parameters in the prospective
setting. In this collaboration, the QIN anticipates an
expansion of radiation-focused, QI-based trials.
The QIN also has a particular interest in the use of
perfusion MRI to detect treatment-resistant regions of dis-
ease and provide guidance for adaptive RT dosing. For
example, in patients with HNC treated with chemo-
radiation, early increases in vascularity identified on DSC-
MRI have demonstrated ability to predict tumor responses
(145), suggesting increased oxygen availability may
correlate with tumor radiosensitivity. DCE-MRI Ktrans
values correlating with tumor heterogeneity also have been
associated with greater radioresistance in HNC (146, 147),
glioblastoma (140), NSCLC (148), and rectal cancer (149).
QIN members are actively using these modalities to iden-
tify subvolumes at greater risk of local failure (150) and
attempting to integrate dose escalation strategies into
clinical trials. This paradigm is highlighted by an ongoing
randomized phase II trial by QIN researchers at the Uni-
versity of Michigan, in which dose painting to hypo-
perfused subvolumes in locally advanced HNC based on
DCE-MRI is performed (NCT02031250). In conjunction
with this trial, steps are under way to improve the stan-
dardization of volume delineation across scanners and
automation of these analyses (151). The QIN is also
rigorously assessing the robustness of MRI-based QI pa-
rameters through quality assurance studies (152) and en-
deavors such as the QIN-sponsored arterial input function
challenge (153).DWI with ADC mapping
DWI is a nonecontrast enhanced sequence that generates
images used to assess the rate of water diffusion. Succes-
sive images are obtained using varying diffusion gradients
to estimate an ADC map. In cancer, restricted diffusion is
caused by hypercellularity and quantified by a low ADC
map value. If there are changes in the tumor, such as cell
death or treatment effect, the ADC value typically
increases.
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in cellular density before apparent anatomic differences
occur (154), its utility for assessing early responses to RT is
of significant interest. Studies have reported using this
strategy for intracranial malignancies (154), HNC (155),
esophageal cancer (156), and prostate cancer (157).
Numerous clinical trials are ongoing which incorporate
DWI/ADC mapping in this fashion, including in esopha-
geal cancer (NCT03151642), HNC (NCT02497573,
NCT00581906), prostate cancer (NCT02319239), rectal
cancer (NCT02233374), pediatric sarcoma
(NCT02415816), and cervical cancer (NCT01992861).
DWI/ADC mapping also has been used to discern re-
currences from radiation effect after RT (158-162). Often
these analyses are performed in combination with [18F]-
FDG PET (160) or other multiparametric MRI modalities
(161, 162).
Additionally, wider availability of 3T MRI with more
powerful gradient subsystems now allows for clinical use of
high b-values for DWI while maintaining adequate signal-
to-noise ratios, which is not typically possible using 1.5T
MRI scanners. High b-values provide better image contrast
and tissue diffusivity measurements, result in less T2 shine-
through effect, and allow less conspicuous features to be
observed (163). In prostate cancer, high b-value DWI (most
commonly in the setting of multiparametric MRI) has been
reported to better identify malignant lesions (163-165),
predict Gleason grade (166, 167), and identify extrac-
apsular extension (168). Interestingly, manual interpretation
has been reported to be superior to region of interestebased
ADC values (165), emphasizing the need for improved
quantitative metrics.
In addition to validating both histogram and voxel-based
DWI/ADC metrics as clinical biomarkers, QIN in-
vestigators at the University of Michigan are actively pur-
suing a standardized acquisition platform for ADC
mapping. Similar to the needs of other QI modalities,
robust quality assurance and standardization of system
performance metrics across scanner vendors will be needed
to improve comparability (169). There is also promise for
advanced image segmentation and image feature analyses
to broaden the capabilities of DWI.
MRS
MRS is a quantitative molecular-based technique that
measures the levels of metabolites within tissue. MRS
data can be either in single-voxel or multivoxel mode,
with multivoxel data acquired using magnetic resonance
spectroscopic imaging (MRSI). In contrast to other mag-
netic resonance modalities, MRSI provides a voxel-based
spectrum of resonance “peaks” rather than an image and is
obtained in conjunction with anatomic MRI sequences to
spatially correlate with regions of interest. MRSI detects
the frequency of various metabolites by nuclear magnetic
resonance, most commonly of 1H in units of parts permillion (ppm). The most common metabolites are N-
acetyl aspartate (NAA), a neuronal metabolite and marker
at 2.2 ppm; creatine/phosphocreatine (Cr), a marker of
energy metabolism at 3.0 ppm; and Cho, a measure of cell
membrane turnover (tumor activity) at 3.2 ppm. Spectra
examples for glioblastoma and contralateral normal brain
are shown in Figure 3A.
Significant effort has been made to use MRSI in brain
tumors. Spectroscopy metrics have demonstrated ability to
differentiate tumor grade (170), and increases in certain
metabolites and their ratios, such as Cho-to-NAA ratio
(Cho/NAA), lipid, and lactate, during treatment have been
associated with worse outcomes and the sites of local re-
currences (171-173). During posttreatment surveillance,
MRSI has been reported to improve specificity between
tumor progression and radiation necrosis. However, for
small tumors, this technique has limited sensitivity (174).
In addition, for infiltrative brain malignancies such as
glioblastoma, a promising use of MRSI includes integrating
metabolite profiles to better define microscopic disease
extension. In one study, regions with pretreatment Cho/
NAA ratios 2 predicted for sites of contrast-enhancing
recurrence, often in regions not originally targeted by
conventional volumes (175). Studies are now integrating
MRSI into RT planning to optimize tumor coverage
(172,173,175-179). QIN investigators at Emory University
are advancing the use of spectroscopy for this purpose
using a recently developed echo planar spectroscopic im-
aging sequence, called spectroscopic MRI (sMRI), that
achieves 3D whole brain coverage at relatively high reso-
lution (nominal voxel size of w5 mm). This group reported
that abnormal pretreatment sMRI volumes predicted for the
sites of eventual glioblastoma recurrence, and the retro-
spective integration of these abnormal volumes (defined at
Cho/NAA thresholds of 1.5, 1.75 and 2.0 greater than
contralateral white matter) into the original treatment plans
would have improved coverage of the recurrent disease
(92.4%, 90.5%, and 88.6%, respectively) compared with
the original treatment (82.5%) while maintaining dosi-
metric constraints (177). An example is shown in Figure 3B
demonstrating regions of disease recurrence that were
previously identified by pretreatment Cho/NAA maps
despite not being apparent on the initial T1 postcontrast or
fluid attenuation inversion recovery (FLAIR) sequences. A
phase II trial at Emory University and Johns Hopkins
University has been initiated that prospectively examines
the predictive value of serial 3D whole brain sMRI for
patients with newly diagnosed glioblastoma treated with
the histone deacetylase inhibitor belinostat along with
standard RT and temozolomide (NCT02137759).
With an improved ability to identify volumes at high risk
of containing subclinical disease several clinical trials are
utilizing MRSI to guide selected dose escalation. Using a
simultaneous integrated boost up to 72 Gy was reported to
be dosimetrically feasible (180), and this strategy is now
the basis for the SPECTRO GLIO trial, a French
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Fig. 3. (A) Spectra from voxels representing glioblastoma (red) or contralateral normal brain (yellow) from a whole brain
echo planar spectroscopic imaging (EPSI) acquisition are shown. Choline (Cho), (creatine) Cr, and N-acetylaspartate (NAA)
peaks are indicated. (B) Pretreatment anatomic (T1 postcontrast and FLAIR), spectroscopic (Cho/NAA map from whole
brain EPSI) sequences, a T1 postcontrast sequence obtained 5 months after radiation therapy of a glioblastoma case are
shown. All sequences were matched using a rigid registration algorithm. Cho/NAA ratio values are normalized to an average
of the normal contralateral white matter Cho/NAA values and presented as a color wash map. A cutoff normalized Cho/NAA
value of 2.0 is used to generate the red contours that are shown, indicating high-risk regions based on the Cho/NAA map.
White arrows denote regions deemed high risk by Cho/NAA map that ultimately failed with contrast-enhancing disease but
showed no evidence of abnormal signal on the pretreatment T1 postcontrast or FLAIR sequences. (A color version of this
figure is available at https://dx.doi.org/10.1016/j.ijrobp.2018.06.023.)
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with or without a simultaneous integrated boost to 72 Gy
directed at the volume defined by a Cho/NAA ratio >2 and
T1 postcontrast enhancement (NCT01507506). In the
United States, the Emory QIN group is leading a single-
arm, multisite pilot study to assess the feasibility and
progression-free survival benefit of dose escalation to
75 Gy using a similar high-risk volume identified on 3T 3D
whole brain sMRI (NCT03137888).
MRSI is also under investigation in prostate cancer.
Normal prostate tissue typically contains high levels of citrate
(2.6 ppm) and Cr and low levels of Cho. Ratios of Cho-to-
citrate and ChoþCr-to-citrate may be helpful in distinguish-
ing normal from malignant tissue and assist with biopsy
planning (181). Molecular atrophy, defined by Cho and cit-
rate peak area-to-noise-ratio<5:1, is known to occur after RT
and negatively correlates with PSA levels and response (182).
After RT, addition of MRSI to T2-weighted MRI improved
the diagnostic accuracy of questionable recurrent lesions
(183). Furthermore, the total Cho-to-Cr ratio (tCho/Cr) frombiopsy samples was reported to predict high-risk versus
indolent disease (2.4  0.4 vs 1.5  0.2) with an accuracy of
95% and may help stratify individual risk and select patients
in need of salvage therapy (184). Additionally, because local
failure after RT most commonly occurs in dominant intra-
prostatic lesions (185), image guided dose escalation has
drawn significant interest (186). Reports using MRSI to guide
brachytherapy dose escalation have reported excellent clin-
ical outcomes and toxicity rates (187, 188), and this may be
an important strategy for patients with unfavorable-
intermediate or high-risk disease.MRI Radiomics and Segmentation
Given the wide range of available textural information,
multiparametric MRI-based radiomic feature analysis has
tremendous potential to provide insights beyond quantified
signal intensity. Numerous QIN teams spearheaded by the
group at Johns Hopkins University are working to extract
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work has evaluated feature profiles to discern benign from
malignant lesions (189), identify radiation necrosis after RT
(190, 191), generate automatic tumor segmentation algo-
rithms (192, 193), and improve prognostic capabilities in
glioblastoma after chemoradiation (194, 195). An inter-
esting example of this approach was pursued by researchers
at the University of Heidelberg, where 181 multiparametric
MRI scans of patients with glioblastoma were analyzed.
From these scans, 1043 imaging features were extracted.
Reproducible image characteristics were identified using
test-retest analyses and subsequently modeled on a dis-
covery cohort to identify a specific radiomic signature
predictive for progression-free and overall survival. This
identified signature was then tested in a multivariate Cox
model using a validation cohort and found to be indepen-
dently associated with outcomes in addition to MGMT
methylation (195).
Deep-learning feature extraction is also being conducted
to recognize patterns specific to genomic phenotypes
(196-198). In prostate cancer, regions of abnormal radiomic
features pathologically confirmed via targeted prostate bi-
opsies were able to discern various gene expression patterns
involved in immune and inflammatory response, meta-
bolism, and cell and biological adhesion (196). Strategic
platforms integrating radiomic information into RT treat-
ment planning are now under development, such as
“Radiomics based targeted radiotherapy planning” (Rad-
TRaP) developed by researchers at Case Western Reserve
University (199). The program generates radiomic-based
brachytherapy dosing or external beam plans based on le-
sions identified by feature analysis on multiparametric MRI
scans, and demonstrated ability to reduce dose to organs at
risk while delivering boosts to the identified lesions.
Further automation has the exciting potential to streamline
radiation oncology workflow while enhancing clinical care.
The QIN remains committed to advancing these endeavors
with the development of imaging processing platforms that
facilitate the discovery and validation of radiomic
biomarkers.Conclusions
A wide range of radiologic QI modalities is being investi-
gated to better characterize tumor characteristics and to
assess radiation treatment effects and outcomes. These
quantitative assessments complement the traditionally
qualitative use of standard imaging methods. The rapid
development of radiologic biomarkers using QI analysis
tools for clinical decision-making is promising, and sub-
sequent integration into daily radiation oncology practice is
expected. To do so, however, will require the field to invest
in rigorous quantification and validation. The most com-
mon applications for these tools are for treatment planning,
risk stratification, guidance of dose escalation, and char-
acterization of posttreatment effects. By collaboratingacross disciplines in a unified goal-oriented network, the
QIN seeks to address the challenges of integrating QI into
the radiation oncology clinical workflow, including identi-
fication and standardization of clinically significant QI
parameters and optimization of existing imaging methods
for RT planning and response assessment. These important
investigations are necessary for the robust integration of
individual patients’ anatomic, biological, physiological,
and genomic imaging characteristics into radiation
oncology decision-making and treatment design, thereby
enabling truly personalized cancer care.References
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